Search Results for: cydy

Biotechnology company CytoDyn (OTCQB: CYDY) this morning announced the appointment of David F. Welch, Ph.D., Founder, Chief Innovation Officer and Director of Infinera Corporation, to the CytoDyn Board of Directors. Dr. Welch has a notable background including strategic planning expertise and broad capital markets experience. As an investor in the company, he appreciates the potential … Continue reading “QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Appoints New Member to Board of Directors”

Biotechnology company CytoDyn (OTCQB: CYDY) this morning announced that it will be presenting at the Biotech Showcase at the Hilton San Francisco Union Square in San Francisco, California on January 9, 2019 at 10:30 AM PT. An update on the company’s clinical development programs and objectives for leronlimab (PRO 140) will be co-presented by president … Continue reading “QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) to Present at Biotech Showcase Conference”

Biotechnology company CytoDyn (OTCQB: CYDY) today announced the election of its Chief Medical Officer and Director Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P. to the additional position of vice chairman of the board of directors. In this added role Pestell, an internationally renowned clinician and cancer researcher and defining force in CCR5 antagonist research, … Continue reading “QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Names Richard G. Pestell, M.D., Ph.D. as Board Vice Chairman, Expanding Leadership Role in Advancement of Company Initiatives”

Biotechnology company CytoDyn (OTCQB: CYDY) today announced that it has named Nitya G. Ray, Ph.D. to serve as its new chief technology officer – head of process sciences, manufacturing & supply chain.  Dr. Ray, from November 2015 to June 2017, served as CytoDyn’s senior vice president of manufacturing.  Most recently, he served Actinium Pharmaceuticals, Inc. … Continue reading “QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Appoints Chief Technology Officer Nitya G. Ray, Ph.D.”

Biotechnology company CytoDyn (OTCQB: CYDY) today announced that its board of directors has appointed Scott A. Kelly, M.D., FAAPMR as its chairman. Dr. Kelly has served on CytoDyn’s board since April 2017, and he succeeds Anthony D. Caracciolo, who will continue to serve as a company director. “We are delighted to have Scott serve as … Continue reading “QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Appoints Dr. Scott Kelly as Chairman of the Board”

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced that President and CEO Nader Pourhassan, Ph.D., and Chief Medical Officer Richard Pestell, M.D., Ph.D., F.A.C.P., M.B.A., will host an investment community conference call on Wednesday, December 12, at 4:00 p.m. ET. To access the call, interested parties should dial 877-407-2986 (U.S. and Canada) or 201-378-4916 … Continue reading “QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) to Host Conference Call, Provide Business Update on December 12, 2018”

Biotechnology company CytoDyn (OTCQB: CYDY) today announced recent clinical study results showing that its PCaTest provides substantial additive value for predicting outcomes for prostate cancer patients compared to the Gleason score, the current standard for prostate cancer diagnosis. The new findings support CYDY’s strategy for seeking FDA approval for the PCaTest. “Unfortunately, current tests not … Continue reading “QualityStocksNewsBreaks – CytoDyn Inc.’s (CYDY) PCaTest Clinical Study Results Demonstrate Added Value to Gleason Score, Further Support FDA filing”

CytoDyn (OTCQB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, this morning announced that Nader Pourhassan, Ph.D., president and CEO and Richard Pestell, M.D., Ph.D., F.A.C.P., M.B.A., Chief Medical Officer, will present at two investment conferences during the month of December. First, taking place on Tuesday, December 4, … Continue reading “QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Scheduled to Present at Two Conferences in December”